Advertisement Pharmaceutical Business review - Page 92 of 5288 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 27, 2026

ViiV Healthcare’s Tivicay PD gains FDA approval for paediatric HIV therapy

The US Food and Drug Administration (FDA) has approved ViiV Healthcare’s Tivicay PD (dolutegravir), for use with other antiretroviral agents in paediatric patients with human immunodeficiency virus type 1 (HIV-1) who weigh at least 2kg.

The studies indicated that dolutegravir reached therapeutic levels in neonates and showed a safety profile similar to older patients. Credit: Gorodenkoff/Shutterstock.com.